It is well known that immunosurveillance affects the prognosis of cancer patients and that tumors can evade immune responses and immunotherapy by taking advantage of immune checkpoint genes, such as PD-1, PD-L1, and CTLA-4 (Gong et al., 2018; Kruger et al., 2019). The gene discussed is PDCD1; the disease is cancer.